Abstract

Despite recent advances, prostate cancer (PCa) remains a leading cause of cancer morbidity and mortality. Clinically, PCa screening methods display low sensitivity and specificity, leading to suboptimal patient care. Recent research suggests that PCa progression is regulated by a coordinated spectrum of epigenetic alterations that notably involves noncoding RNAs. These molecular aberrations drive PCa progression by inducing gene expression programs that promote metastatic dissemination. Epigenetic proteins and noncoding RNAs can be detected noninvasively in body fluids, allowing improved PCa screening and prognosis. In addition, epigenetic alterations can be targeted pharmacologically, providing unprecedented therapeutic opportunities. This work reviews the current literature linking epigenetic dysregulation and PCa progression and proposes a framework for integrating epigenetic strategies into the clinical management of PCa.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Sung H, Ferlay J et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
MedlineGoogle Scholar
2. U.S.P.S.T. Force, Grossman DC, Curry SJ, Owens DK et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319, 1901–1913 (2018). • This article provides recommendations with regards to prostate cancer (PCa) screening.
MedlineGoogle Scholar
3. Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat. Rev. Urol. 19, 562–572 (2022).
MedlineGoogle Scholar
4. Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J. Urol. 4, 86–95 (2017).
Medline CASGoogle Scholar
5. Heijnsdijk EAM, Gulati R, Tsodikov A et al. Lifetime benefits and harms of prostate-specific antigen-based risk-stratified screening for prostate cancer. J. Natl Cancer Inst. 112, 1013–1020 (2020).
Medline CASGoogle Scholar
6. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J. Clin. Oncol. 28, 3951–3957 (2010).
MedlineGoogle Scholar
7. Ilic D, Djulbegovic M, Jung JH et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362, k3519 (2018).
MedlineGoogle Scholar
8. Loeb S, Vellekoop A, Ahmed HU et al. Systematic review of complications of prostate biopsy. Eur. Urol. 64, 876–892 (2013).
MedlineGoogle Scholar
9. Borley N, Feneley MR. Prostate cancer: diagnosis and staging. Asian J. Androl. 11, 74–80 (2009).
MedlineGoogle Scholar
10. Cristea O, Lavallee LT, Montroy J et al. Active surveillance in Canadian men with low-grade prostate cancer. CMAJ 188, E141–E147 (2016).
MedlineGoogle Scholar
11. Hamdy FC, Donovan JL, Lane JA et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).
MedlineGoogle Scholar
12. Potosky AL, Davis WW, Hoffman RM et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J. Natl Cancer Inst. 96, 1358–1367 (2004).
MedlineGoogle Scholar
13. Banerjee R, Smith J, Eccles MR, Weeks RJ, Chatterjee A. Epigenetic basis and targeting of cancer metastasis. Trends Cancer 8, 226–241 (2022).
Medline CASGoogle Scholar
14. Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J. Biomed. Sci. 28, 27 (2021).
Medline CASGoogle Scholar
15. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 23, 781–783 (2009).
Medline CASGoogle Scholar
16. Jerkovic I, Cavalli G. Understanding 3D genome organization by multidisciplinary methods. Nat. Rev. Mol. Cell Biol. 22, 511–528 (2021).
Medline CASGoogle Scholar
17. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science 330, 612–616 (2010).
Medline CASGoogle Scholar
18. Zhang P, Torres K, Liu X, Liu CG, Pollock RE. An overview of chromatin-regulating proteins in cells. Curr. Protein Pept. Sci. 17, 401–410 (2016).
Medline CASGoogle Scholar
19. Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science 187, 226–232 (1975).
Medline CASGoogle Scholar
20. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395 (2011).
Medline CASGoogle Scholar
21. Biswas S, Rao CM. Epigenetic tools (the writers, the readers and the erasers) and their implications in cancer therapy. Eur. J. Pharmacol. 837, 8–24 (2018).
Medline CASGoogle Scholar
22. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13, 343–357 (2012).
Medline CASGoogle Scholar
23. Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem. Cell Biol. 83, 344–353 (2005).
Medline CASGoogle Scholar
24. Richard Boland C. Non-coding RNA: it's not junk. Dig. Dis. Sci. 62, 1107–1109 (2017).
MedlineGoogle Scholar
25. Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 33, 1–16 (2014).
Medline CASGoogle Scholar
26. Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157, 77–94 (2014).
Medline CASGoogle Scholar
27. Qian Y, Shi L, Luo Z. Long non-coding RNAs in cancer: implications for diagnosis, prognosis, and therapy. Front. Med. (Lausanne) 7, 612393 (2020).
MedlineGoogle Scholar
28. Chen J, Wang Y, Wang C, Hu JF, Li W. LncRNA functions as a new emerging epigenetic factor in determining the fate of stem cells. Front. Genet. 11, 277 (2020).
Medline CASGoogle Scholar
29. Mirzaei S, Gholami MH, Hushmandi K et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J. Hematol. Oncol. 15, 18 (2022).
Medline CASGoogle Scholar
30. John RM, Rougeulle C. Developmental epigenetics: phenotype and the flexible epigenome. Front. Cell Dev. Biol. 6, 130 (2018).
MedlineGoogle Scholar
31. Liu Y, Liu B, Jin G et al. An integrated three-long non-coding RNA signature predicts prognosis in colorectal cancer patients. Front. Oncol. 9, 1269 (2019).
MedlineGoogle Scholar
32. Grillone K, Riillo C, Scionti F et al. Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”. J. Exp. Clin. Cancer Res. 39, 117 (2020).
Medline CASGoogle Scholar
33. Baca SC, Garraway LA. The genomic landscape of prostate cancer. Front. Endocrinol. (Lausanne) 3, 69 (2012).
MedlineGoogle Scholar
34. Lopez J, Anazco-Guenkova AM, Monteagudo-Garcia O, Blanco S. Epigenetic and epitranscriptomic control in prostate cancer. Genes (Basel) 13, (2022).
Google Scholar
35. Barbieri CE, Baca SC, Lawrence MS et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).
Medline CASGoogle Scholar
36. Lin D, Wyatt AW, Xue H et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272–1283 (2014).
Medline CASGoogle Scholar
37. Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology 38, 23–38 (2013).
Medline CASGoogle Scholar
38. Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. J. Steroid Biochem. Mol. Biol. 166, 1–15 (2017).
Medline CASGoogle Scholar
39. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 18, 1313–1324 (1999).
Medline CASGoogle Scholar
40. Graca I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jeronimo C. Epigenetic modulators as therapeutic targets in prostate cancer. Clin. Epigenetics 8, 98 (2016).
MedlineGoogle Scholar
41. Chinaranagari S, Sharma P, Bowen NJ, Chaudhary J. Prostate cancer epigenome. Methods Mol. Biol. 1238, 125–140 (2015).
MedlineGoogle Scholar
42. Cang S, Feng J, Konno S et al. Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. Int. J. Oncol. 35, 1417–1422 (2009).
Medline CASGoogle Scholar
43. Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front. Cell Dev. Biol. 8, 576946 (2020).
MedlineGoogle Scholar
44. Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol. 8, 92 (2018).
MedlineGoogle Scholar
45. Hontecillas-Prieto L, Flores-Campos R, Silver A, de Alava E, Hajji N, Garcia-Dominguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front. Genet. 11, 578011 (2020).
Medline CASGoogle Scholar
46. Biersack B, Nitzsche B, Hopfner M. HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer. Cancer Drug Resist. 5, 64–79 (2022).
Medline CASGoogle Scholar
47. Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther. Adv. Urol. 7, 388–395 (2015).
Medline CASGoogle Scholar
48. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
Medline CASGoogle Scholar
49. Clermont PL, Crea F, Chiang YT et al. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin. Epigenetics 8, 16 (2016). • This article identifies CBX2 as a potential biomarker and therapeutic target in PCa.
MedlineGoogle Scholar
50. Blackledge NP, Klose RJ. The molecular principles of gene regulation by polycomb repressive complexes. Nat. Rev. Mol. Cell Biol. 22, 815–833 (2021).
Medline CASGoogle Scholar
51. Guo Y, Zhao S, Wang GG. Polycomb gene silencing mechanisms: PRC2 chromatin targeting, H3K27me3 ‘readout’, and phase separation-based compaction. Trends Genet. 37, 547–565 (2021).
Medline CASGoogle Scholar
52. Yu J, Yu J, Rhodes DR et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657–10663 (2007). •• This article highlights the potential of EZH2 genomic targets as biomarkers in PCa.
Medline CASGoogle Scholar
53. Ngollo M, Lebert A, Daures M et al. Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression. BMC Cancer 17, 261 (2017).
MedlineGoogle Scholar
54. Das P, Taube JH. Regulating methylation at H3K27: a trick or treat for cancer cell plasticity. Cancers (Basel) 12, (2020).
Google Scholar
55. Kraft K, Yost KE, Murphy SE et al. Polycomb-mediated genome architecture enables long-range spreading of H3K27 methylation. Proc. Natl Acad. Sci. USA 119, e2201883119 (2022).
Medline CASGoogle Scholar
56. Mu W, Starmer J, Yee D, Magnuson T. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation. Epigenetics Chromatin 11, 71 (2018).
Medline CASGoogle Scholar
57. Kawaguchi T, Machida S, Kurumizaka H, Tagami H, Nakayama JI. Phosphorylation of CBX2 controls its nucleosome-binding specificity. J. Biochem. 162, 343–355 (2017).
Medline CASGoogle Scholar
58. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor–a marker or mover of metastatic prostate cancer? Cancer Cell 2, 349–350 (2002).
Medline CASGoogle Scholar
59. Clermont PL, Lin D, Crea F et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 7, 40 (2015).
MedlineGoogle Scholar
60. Bai Y, Zhang Z, Cheng L et al. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. J. Biol. Chem. 294, 9911–9923 (2019). •• This study highlights the therapeutic potential of EZH2 as a drug target in advanced PCa.
Medline CASGoogle Scholar
61. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell 4, 331–341 (2013).
Medline CASGoogle Scholar
62. Kang N, Eccleston M, Clermont PL et al. EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics 12, 1457–1476 (2020).
CASGoogle Scholar
63. Clermont PL, Sun L, Crea F et al. Genotranscriptomic meta-analysis of the polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. Br. J. Cancer 111, 1663–1672 (2014).
Medline CASGoogle Scholar
64. Wang S, Alpsoy A, Sood S et al. Selective CBX2 chromodomain ligand and its cellular activity during prostate cancer neuroendocrine differentiation. Chembiochem 22, 2335–2344 (2021).
Medline CASGoogle Scholar
65. Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Epigenetics in prostate cancer: clinical implications. Transl. Androl. Urol. 10, 3104–3116 (2021).
MedlineGoogle Scholar
66. Ci X, Hao J, Dong X et al. Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer. Cancer Res. 78, 2691–2704 (2018).
Medline CASGoogle Scholar
67. Crea F, Sun L, Mai A et al. The emerging role of histone lysine demethylases in prostate cancer. Mol. Cancer 11, 52 (2012).
Medline CASGoogle Scholar
68. Parolia A, Cieslik M, Chu SC et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571, 413–418 (2019).
Medline CASGoogle Scholar
69. Asangani IA, Dommeti VL, Wang X et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278–282 (2014). • This article details the targeting of the epigenetic regulator BRD4.
Medline CASGoogle Scholar
70. Wang Y, Yu J. Dissecting multiple roles of SUMOylation in prostate cancer. Cancer Lett. 521, 88–97 (2021).
Medline CASGoogle Scholar
71. Mahajan K, Malla P, Lawrence HR et al. ACK1/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell 31, 790–803 e8 (2017).
Medline CASGoogle Scholar
72. Nag N, Dutta S. Deubiquitination in prostate cancer progression: role of USP22. J. Cancer Metastasis Treat. 6, (2020).
MedlineGoogle Scholar
73. Izzo LT, Affronti HC, Wellen KE. The bidirectional relationship between cancer epigenetics and metabolism. Ann. Rev. Cancer Biol. 5, 235–257 (2021).
MedlineGoogle Scholar
74. Kumar S, Gonzalez EA, Rameshwar P, Etchegaray JP. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel) 12, (2020).
Google Scholar
75. Yang X, Liu M, Li M et al. Epigenetic modulations of noncoding RNA: a novel dimension of cancer biology. Mol. Cancer 19, 64 (2020).
MedlineGoogle Scholar
76. Lemos AEG, Matos ADR, Ferreira LB, Gimba ERP. The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget 10, 6589–6603 (2019).
MedlineGoogle Scholar
77. Pepe P, Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res. 31, 4445–4449 (2011). •• This article directly compares prostate-specific antigen and PCA3.
MedlineGoogle Scholar
78. Rendon RA, Mason RJ, Marzouk K et al. Recommandations de l'Association des urologues du Canada sur le depistage et le diagnostic precoce du cancer de la prostate. Can. Urol. Assoc. J. 11, 298–309 (2017).
MedlineGoogle Scholar
79. Prensner JR, Iyer MK, Sahu A et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45, 1392–1398 (2013).
Medline CASGoogle Scholar
80. Mehra R, Udager AM, Ahearn TU et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur. Urol. 70, 549–552 (2016).
Medline CASGoogle Scholar
81. Chang J, Xu W, Du X, Hou J. MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS. Onco Targets Ther. 11, 3461–3473 (2018).
MedlineGoogle Scholar
82. Jiang G, Su Z, Liang X, Huang Y, Lan Z, Jiang X. Long non-coding RNAs in prostate tumorigenesis and therapy. Mol. Clin. Oncol. 13, 76 (2020).
Medline CASGoogle Scholar
83. Parolia A, Crea F, Xue H et al. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Mol. Cancer 14, 46 (2015).
MedlineGoogle Scholar
84. Parolia A, Venalainen E, Xue H et al. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. Mol. Oncol. 13, 1121–1136 (2019).
Medline CASGoogle Scholar
85. Crea F, Watahiki A, Quagliata L et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 5, 764–774 (2014).
MedlineGoogle Scholar
86. Crea F, Venalainen E, Ci X et al. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics 8, 721–731 (2016).
CASGoogle Scholar
87. Mather RL, Parolia A, Carson SE et al. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. Mol. Oncol. 15, 1921–1941 (2021).
Medline CASGoogle Scholar
88. Pucci P, Venalainen E, Alborelli I et al. LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. Epigenomics 12, 1123–1138 (2020).
CASGoogle Scholar
89. Misawa A, Takayama KI, Inoue S. Long non-coding RNAs and prostate cancer. Cancer Sci. 108, 2107–2114 (2017).
Medline CASGoogle Scholar
90. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008).
Medline CASGoogle Scholar
91. Abramovic I, Ulamec M, Katusic Bojanac A, Bulic-Jakus F, Jezek D, Sincic N. miRNA in prostate cancer: challenges toward translation. Epigenomics 12, 543–558 (2020).
CASGoogle Scholar
92. Crea F, Quagliata L, Michael A et al. Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Mol. Oncol. 10, 693–703 (2016).
Medline CASGoogle Scholar
93. Martens-Uzunova ES, Hoogstrate Y, Kalsbeek A et al. C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer. Oncotarget 6, 17430–17444 (2015).
MedlineGoogle Scholar
94. Greene J, Baird AM, Casey O et al. Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci. Rep. 9, 10739 (2019).
MedlineGoogle Scholar
95. Ronnau CG, Verhaegh GW, Luna-Velez MV, Schalken JA. Noncoding RNAs as novel biomarkers in prostate cancer. Biomed. Res. Int. 2014, 591703 (2014).
Medline CASGoogle Scholar
96. Bell N, Connor Gorber S, Shane A et al. Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 186, 1225–1234 (2014).
MedlineGoogle Scholar
97. Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene 34, 1609–1618 (2015).
Medline CASGoogle Scholar
98. Durand X, Moutereau S, Xylinas E, de la Taille A. Progensa PCA3 test for prostate cancer. Expert Rev. Mol. Diagn. 11, 137–144 (2011).
Medline CASGoogle Scholar
99. Malavaud B, Cussenot O, Mottet N et al. Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France. J. Med. Econ. 16, 358–363 (2013).
MedlineGoogle Scholar
100. D'Adamo GL, Widdop JT, Giles EM. The future is now? Clinical and translational aspects of “omics” technologies. Immunol. Cell Biol. 99, 168–176 (2021).
MedlineGoogle Scholar
101. Helsmoortel H, Everaert C, Lumen N, Ost P, Vandesompele J. Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: hype or hope? Noncoding RNA Res. 3, 64–74 (2018).
Medline CASGoogle Scholar
102. Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers (Basel) 11, (2019).
Google Scholar
103. Santos V, Freitas C, Fernandes MG et al. Liquid biopsy: the value of different bodily fluids. Biomark. Med. 16, 127–145 (2022).
CASGoogle Scholar
104. Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis. Oncol. 3, (2019).
Google Scholar
105. Hutchinson R, Lotan Y. Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer. Transl. Androl. Urol. 6, 345–354 (2017).
MedlineGoogle Scholar
106. Schneider JE, Sidhu MK, Doucet C, Kiss N, Ohsfeldt RL, Chalfin D. Economics of cancer biomarkers. Per. Med. 9, 829–837 (2012).
CASGoogle Scholar
107. Qian Y, Daza J, Itzel T et al. Prognostic cancer gene expression signatures: current status and challenges. Cells 10, (2021).
Google Scholar
108. Huo X, Zhou X, Peng P et al. Identification of a six-gene signature for predicting the overall survival of cervical cancer patients. Onco Targets Ther. 14, 809–822 (2021).
MedlineGoogle Scholar
109. Shi K, Lin W, Zhao XM. Identifying molecular biomarkers for diseases with machine learning based on integrative omics. IEEE/ACM Trans. Comput. Biol. Bioinform. 18, 2514–2525 (2021).
Medline CASGoogle Scholar
110. Zeuschner P, Linxweiler J, Junker K. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev. Mol. Diagn. 20, 151–167 (2020).
Medline CASGoogle Scholar
111. Deng J, Tang J, Wang G, Zhu YS. Long non-coding RNA as potential biomarker for prostate cancer: is it making a difference? Int. J. Environ. Res. Public Health 14, (2017).
Google Scholar
112. Locke WJ, Guanzon D, Ma C et al. DNA methylation cancer biomarkers: translation to the clinic. Front. Genet. 10, 1150 (2019).
Medline CASGoogle Scholar
113. Gurioli G, Martignano F, Salvi S, Costantini M, Gunelli R, Casadio V. GSTP1 methylation in cancer: a liquid biopsy biomarker? Clin. Chem. Lab. Med. 56, 702–717 (2018).
Medline CASGoogle Scholar
114. Sinnott JA, Peisch SF, Tyekucheva S et al. Prognostic utility of a new mRNA expression signature of Gleason Score. Clin. Cancer Res. 23, 81–87 (2017).
Medline CASGoogle Scholar
115. Huang TB, Dong CP, Zhou GC et al. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival. Int. Urol. Nephrol. 49, 825–835 (2017).
Medline CASGoogle Scholar
116. Xin L, Liu YH, Martin TA, Jiang WG. The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint. World J. Oncol. 8, 34–40 (2017).
Medline CASGoogle Scholar
117. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin. Adv. Hematol. Oncol. 11, 14–23 (2013).
MedlineGoogle Scholar
118. Lam D, Clark S, Stirzaker C, Pidsley R. Advances in prognostic methylation biomarkers for prostate cancer. Cancers (Basel) 12, (2020).
Google Scholar
119. Bates SE. Epigenetic therapies for cancer. N. Engl. J. Med. 383, 650–663 (2020).
Medline CASGoogle Scholar
120. Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br. J. Cancer 108, 748–754 (2013).
Medline CASGoogle Scholar
121. Frame FM, Pellacani D, Collins AT et al. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br. J. Cancer 109, 3023–3033 (2013).
Medline CASGoogle Scholar
122. Xiao W, Graham PH, Hao J et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLOS ONE 8, e74253 (2013).
Medline CASGoogle Scholar
123. Crea F, Hurt EM, Mathews LA et al. Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer 10, 40 (2011).
Medline CASGoogle Scholar
124. Milosevich N, McFarlane J, Gignac MC et al. Pan-specific and partially selective dye-labeled peptidic inhibitors of the polycomb paralog proteins. Bioorg. Med. Chem. 28, 115176 (2020).
Medline CASGoogle Scholar
125. Gieni RS, Ismail IH, Campbell S, Hendzel MJ. Polycomb group proteins in the DNA damage response: a link between radiation resistance and “stemness”. Cell Cycle 10, 883–894 (2011).
Medline CASGoogle Scholar
126. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).
Medline CASGoogle Scholar
127. Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 357027 (2014).
MedlineGoogle Scholar
128. Jeyakumar A, Younis T. Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. Clin. Med. Insights Oncol. 6, 179–187 (2012).
Medline CASGoogle Scholar
129. Yan W, Herman JG, Guo M. Epigenome-based personalized medicine in human cancer. Epigenomics 8, 119–133 (2016).
CASGoogle Scholar
130. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629–651 (2021).
Medline CASGoogle Scholar
131. Quemener AM, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert MD. The powerful world of antisense oligonucleotides: from bench to bedside. Wiley Interdiscip. Rev. RNA 11, e1594 (2020).
MedlineGoogle Scholar
132. Mahmoodi Chalbatani G, Dana H, Gharagouzloo E et al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int. J. Nanomedicine 14, 3111–3128 (2019).
MedlineGoogle Scholar
133. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
Medline CASGoogle Scholar
134. Herkt M, Thum T. Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics. Mol. Ther. 29, 521–539 (2021).
Medline CASGoogle Scholar
135. Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery: from reality to dreams. Clin. Epigenetics 11, 174 (2019).
Medline CASGoogle Scholar
136. Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering anti-cancer drugs via computational methods. Front. Pharmacol. 11, 733 (2020).
Medline CASGoogle Scholar

Vol. 15, No. 2

Metrics

Downloaded 110 times

History

Received 10 February 2023

Accepted 7 March 2023

Published online 28 March 2023

Published in print January 2023

Information

Keywords

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer

Abstract

References